Ribon Therapeutics, Inc.
3 clinical trials · Sponsor
◉ Watch Ribon Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| RBN-2397 in Combination With Pembrolizumab in Patients With SCCL (NCT05127590) | Ribon Therapeutics, Inc. | 2022-03-15 |
| SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects (NCT05215808) | Ribon Therapeutics, Inc. | 2022-03-07 |
| Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors (NCT04053673) | Ribon Therapeutics, Inc. | 2019-08-01 |
Track Ribon Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.